MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds
Global pharmaceutical company Merck (NYSE:MRK) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 4.7% year on year to $18.09 billion. The company expects the full year’s revenue to be around $67.05 billion, close to analysts’ estimates. Its non-GAAP profit of $2.49 per share was 19.3% above analysts’ consensus estimates.
Is now the time to buy MRK? Find out in our full research report (it’s free for active Edge members).
Merck (MRK) Q3 2026 highlights:
- Revenue $18.09 billion vs S&P analysts’ estimates of $17.31 billion (4.7% year-on-year growth, 4.5% beat)
- Adjusted EPS $2.49 vs S&P analysts’ estimates of $2.09 (19.3% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $67.05 billion at the midpoint from $66.8 billion
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $2.80 at the midpoint, a 3.1% increase
- Operating margin 30.9%, down from 37.7% in the same quarter last year
- Constant currency revenue rose 4% year on year, in line with the same quarter last year
- Market capitalization $361 billion
StockStory’s take
Merck’s third quarter was marked by strong execution in both its oncology and animal health businesses, with sales momentum driven by new product launches and expansion of key therapies. Management highlighted the successful roll-out of KEYTRUDA QLEX and robust demand for GARDASIL, while also pointing to clinical milestones in oncology and ophthalmology as central to the quarter’s performance. CEO Rob Davis stated, “The breadth of these achievements strengthens my confidence in the future of our company,” underscoring the impact of recent clinical readouts and product uptake.
Looking ahead, Merck’s updated guidance relies on the scaling of new launches, advancing its late-stage pipeline, and continued investment in R&D. Management emphasized the importance of pipeline diversity, with CFO Caroline Litchfield noting, “We remain focused on successfully executing our launches, broadening and advancing our pipeline, and making meaningful investments to realize the full potential of these opportunities.” The company also acknowledged near-term headwinds from generic competition and moderating growth in established products but remains confident in its ability to offset these challenges through innovation and portfolio expansion.
Key insights from management’s remarks
Management attributed quarterly strength to new product momentum in oncology, vaccines, and animal health, while also citing significant clinical trial readouts and regulatory progress as key differentiators.
KEYTRUDA family expansion: The company reported robust uptake of KEYTRUDA and KEYTRUDA QLEX, with global growth fueled by increased use in earlier stage cancers and combination regimens, particularly in indications such as cervical and breast cancer. Management noted that the introduction of KEYTRUDA QLEX (subcutaneous formulation) has driven adoption in the U.S. and high-adoption international markets, despite ongoing litigation challenges in some European countries.
New oncology assets progress: WELIREG sales climbed on the back of increased use in renal cell carcinoma and ongoing international launches. Additionally, the company’s TroFuse program for sac-TMT achieved positive phase III results in endometrial cancer, reinforcing Merck’s leadership in antibody-drug conjugates and bolstering confidence in broader indications such as lung and breast cancer.
Vaccine portfolio resilience: GARDASIL experienced double-digit sales growth, especially in the U.S., supported by CDC purchasing and pricing. Though pneumococcal vaccine sales were mixed, the company is progressing launches in international markets and monitoring shifts in adult vaccination rates.
Cardiometabolic and respiratory launches: WINREVAIR and OHTUVAYRE both contributed to the quarter, with WINREVAIR showing strong demand among pulmonary arterial hypertension patients. The first signs of LIPFENDRA’s uptake are positive, but management cautions that early sales are supported by couponing and sampling, with broad access still in development.
Pipeline and clinical milestones: The quarter featured multiple key clinical readouts, including the intismeran cancer vaccine in melanoma and remigromig in diabetic macular edema, as well as regulatory approvals for new oncology and ophthalmology indications. These results provide greater visibility into Merck’s late-stage pipeline and future growth drivers.
Drivers of future performance
Merck’s outlook is shaped by both the anticipated growth from its expanding product portfolio and the need to navigate near-term pressures from competition and policy changes.
Pipeline launches and uptake: The company expects future growth to hinge on successful commercialization of new therapies in oncology, cardiometabolic, and immunology segments. Management believes advancing assets such as sac-TMT, intismeran, and tulisokibart into broader indications can offset revenue declines from loss of exclusivity on legacy products.
Headwinds from generics and pricing: Merck anticipates moderate revenue growth in upcoming years, with pressure from generic competition in products like BRIDION and JANUVIA, as well as pricing challenges in certain ex-U.S. markets. Policy developments, particularly in Germany, and shifting vaccine utilization trends are also noted as risks.
Margin and investment dynamics: While gross margins may benefit from royalty roll-offs, operating expenses are projected to rise at a mid to high single-digit rate, reflecting investments in R&D and ongoing launches. Management remains committed to capital allocation for pipeline expansion, even as near-term profit margins come under pressure.
Catalysts in upcoming quarters
Going forward, the StockStory team will be monitoring (1) the pace of adoption and payer access for newly launched products like KEYTRUDA QLEX and LIPFENDRA, (2) clinical and regulatory milestones in the late-stage pipeline, particularly for sac-TMT and intismeran, and (3) how Merck manages headwinds from generic competition and shifting vaccine trends. Progress in scaling new indications and maintaining margin discipline will be key to tracking execution.
Merck currently trades at $149.27, up from $141 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).
Now could be the perfect time to invest in these stocks
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
